JP2009515994A5 - - Google Patents

Download PDF

Info

Publication number
JP2009515994A5
JP2009515994A5 JP2008541372A JP2008541372A JP2009515994A5 JP 2009515994 A5 JP2009515994 A5 JP 2009515994A5 JP 2008541372 A JP2008541372 A JP 2008541372A JP 2008541372 A JP2008541372 A JP 2008541372A JP 2009515994 A5 JP2009515994 A5 JP 2009515994A5
Authority
JP
Japan
Prior art keywords
ratio
use according
random copolymer
composition
residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008541372A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009515994A (ja
JP5676079B2 (ja
Filing date
Publication date
Priority claimed from US11/283,405 external-priority patent/US20060194725A1/en
Application filed filed Critical
Publication of JP2009515994A publication Critical patent/JP2009515994A/ja
Publication of JP2009515994A5 publication Critical patent/JP2009515994A5/ja
Application granted granted Critical
Publication of JP5676079B2 publication Critical patent/JP5676079B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2008541372A 2005-11-17 2006-11-17 ランダムコポリマーによる不要な免疫応答の処置方法 Expired - Fee Related JP5676079B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/283,405 2005-11-17
US11/283,405 US20060194725A1 (en) 2004-05-07 2005-11-17 Methods of treating disease with random copolymers
PCT/US2006/044699 WO2007078443A2 (en) 2005-11-17 2006-11-17 Methods of treating unwanted immune response with random copolymers

Publications (3)

Publication Number Publication Date
JP2009515994A JP2009515994A (ja) 2009-04-16
JP2009515994A5 true JP2009515994A5 (cg-RX-API-DMAC7.html) 2009-10-22
JP5676079B2 JP5676079B2 (ja) 2015-02-25

Family

ID=38016876

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008541372A Expired - Fee Related JP5676079B2 (ja) 2005-11-17 2006-11-17 ランダムコポリマーによる不要な免疫応答の処置方法

Country Status (6)

Country Link
US (2) US20060194725A1 (cg-RX-API-DMAC7.html)
EP (1) EP1962880A2 (cg-RX-API-DMAC7.html)
JP (1) JP5676079B2 (cg-RX-API-DMAC7.html)
AU (1) AU2006333437B2 (cg-RX-API-DMAC7.html)
CA (1) CA2630364A1 (cg-RX-API-DMAC7.html)
WO (1) WO2007078443A2 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655221B2 (en) * 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
US20090275496A1 (en) * 2004-05-07 2009-11-05 Peptimmune, Inc. Effective quantitation of complex peptide mixtures in tissue samples and improved therapeutic methods
US20060194725A1 (en) * 2004-05-07 2006-08-31 James Rasmussen Methods of treating disease with random copolymers
US7589063B2 (en) * 2004-12-14 2009-09-15 Aplagen Gmbh Molecules which promote hematopoiesis
US20070087029A1 (en) * 2005-10-14 2007-04-19 Pakala Syamasundar V Localized delivery to the lymphatic system
US20080131441A1 (en) * 2006-09-26 2008-06-05 Manikkam Suthanthiran Methods of Using FOXP3 Levels to Predict the Outcome of Organs Undergoing Acute Rejection
AP3467A (en) 2007-10-16 2015-11-30 Peptimmune Inc Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes
RS55607B1 (sr) 2009-08-20 2017-06-30 Yeda Research & Development Company Ltd Niskofrekventna terapija glatiramer acetatom
MX2012005749A (es) * 2009-11-17 2012-10-03 Ares Trading Sa Metodos para mejorar el diseño, la biodisponibilidad de composiciones de polimero de secuencia dirigida, por medio de la deteccion basada en proteinas del suero, de composiciones de polimero de secuencia dirigida.
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
SG10201806573TA (en) * 2012-05-25 2018-09-27 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
EP3478316A1 (en) * 2016-07-01 2019-05-08 Declion Holdings LLC Amino acid copolymer compositions and uses thereof
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
AU2017319728B2 (en) 2016-08-31 2024-09-05 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
IL316573A (en) 2017-03-26 2024-12-01 Mapi Pharma Ltd Storage systems containing glatiramer acetate for the treatment of multiple sclerosis
US11715467B2 (en) 2019-04-17 2023-08-01 Tempus Labs, Inc. Collaborative artificial intelligence method and system
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド 1型糖尿病を予防するための方法および組成物
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
IL302604A (en) 2020-11-10 2023-07-01 Palena Therapeutics Inc Epitope-Encapsulated Random Peptide (EERP) Preparations for the Treatment of Immune-Mediated Conditions and Methods of Use
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) * 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US5858964A (en) * 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
EP1391206B1 (en) * 1997-10-15 2008-07-02 Polarx Biopharmaceuticals, Inc. Pharmaceutical compositions comprising arsenic trioxide for the treatment of non-Hodgkin's lymphoma
HK1054507B (zh) * 2000-01-20 2008-10-31 耶达研究及发展有限公司 共聚物1和相关肽和多肽及其处理过的t细胞在神经保护性治疗中的用途
EP1188433B1 (en) * 2000-09-14 2007-01-03 Firmenich Sa Use of unsaturated esters as perfuming ingredients
IL161121A0 (en) * 2001-10-03 2004-08-31 Harvard College Copolymers for suppression of autoimmune diseases, and methods of use
US20060194725A1 (en) * 2004-05-07 2006-08-31 James Rasmussen Methods of treating disease with random copolymers
CA2565819A1 (en) * 2004-05-07 2005-12-01 Peptimmune, Inc. Methods of treating disease with random copolymers

Similar Documents

Publication Publication Date Title
RU2461571C2 (ru) Белки, связывающие il-12/p40
US7892563B2 (en) Methods for treatment of severe acute respiratory syndrome (SARS)
CA2947947C (en) New indications for anti-il-1-beta therapy
JP2006523682A5 (cg-RX-API-DMAC7.html)
JP2021531826A5 (cg-RX-API-DMAC7.html)
JP2019509257A5 (cg-RX-API-DMAC7.html)
KR20200142597A (ko) 다발경화증 치료용 조합 요법
JP2008540447A5 (cg-RX-API-DMAC7.html)
JP2007512243A5 (cg-RX-API-DMAC7.html)
JP2013539352A5 (cg-RX-API-DMAC7.html)
JP2005538034A5 (cg-RX-API-DMAC7.html)
KR20250010141A (ko) (3S,4R)-3-에틸-4-(3H-이미다조[1,2-a]피롤로[2,3-e]-피라진-8-일)-N-(2,2,2-트리플루오로에틸)피롤리딘-1-카복스아미드및 이의 고체상 형태의 제조 방법
JP2006519228A5 (ja) 抗原に対し霊長類を免疫寛容化する抗体の使用法
JP2025024041A5 (cg-RX-API-DMAC7.html)
JP2015172060A5 (cg-RX-API-DMAC7.html)
JP2015527357A (ja) 単一可変ドメインとカモスタットメシル酸塩(cm)とを含んでなる組成物
CA2876012A1 (en) Pharmaceutical formulation
Gerner et al. Targeting T and B lymphocytes in inflammatory bowel diseases: lessons from clinical trials
JP2006511620A5 (cg-RX-API-DMAC7.html)
JP2024540275A5 (cg-RX-API-DMAC7.html)
JP2006508039A5 (cg-RX-API-DMAC7.html)
JP2022529929A5 (cg-RX-API-DMAC7.html)
JP2021501800A5 (cg-RX-API-DMAC7.html)
Craddock et al. Immunomodulatory therapies for relapsing-remitting multiple sclerosis: monoclonal antibodies, currently approved and in testing
JP2022513072A5 (cg-RX-API-DMAC7.html)